Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia
Inotuzumab ozogamicin (InO) provides a safe and effective treatment option for patients with relapsed/refractory acute lymphoblastic leukaemia (R/R ALL) with a high disease burden, a recent study has found.
Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia
08 Sep 2020
